FDA Approved: REVCOVI — Supplemental Application (Chiesi USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for REVCOVI (elapegademase-lvlr) by Chiesi USA, Inc., resulting in changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosine Deaminase Deficiency Associated Severe Combined Immunodeficiency

Drugs mentioned

• Revcovi (elapegadamase-lvlr)

Snippet

SUPPL AP for REVCOVI (ELAPEGADEMASE-LVLR)